NCT06492317View on ClinicalTrials.gov

RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 6, 2024

Primary Completion Date

July 6, 2026

Study Completion Date

July 6, 2027

Conditions
HER2-positive Gastric Cancer
Interventions
DRUG

Disitamab Vedotin

Disitamab Vedotin: 2.5mg/kg, d1, ivdrip, Q2W (every 2 weeks)

DRUG

Cadonilimab

Cadonilimab: 6mg/kg, d1, ivdrip, Q2W (every 2 weeks)

Trial Locations (1)

450052

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Zhengzhou University

OTHER

NCT06492317 - RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter